Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Cancer Res. 2011 Sep 6;71(21):6764–6772. doi: 10.1158/0008-5472.CAN-11-0691

Figure 5. NSCLC tumors demonstrate decreased microvessel density and tumor vascular area following itraconazole treatment.

Figure 5

HOE signal from (A) perfused LX-14 tumor and (B) perfused LX-7 sections demonstrate marked decrease in perfusion-competent microvessel density in itraconazole treated tumors. (C & D) Mean ± SEM HOE-positive tumor vascular area in (C) LX-14 tumors treated with vehicle (n=5), itraconazole (ITRA, n=6), cisplatin (CDDP, n=5), or combination itraconazole and cisplatin (ITRA+CDDP, n=7); (D) LX-7 tumors treated with vehicle (n=5), itraconazole (ITRA, n=5), cisplatin (CDDP, n=5), or combination itraconazole and cisplatin (ITRA+CDDP, n=5).

HHS Vulnerability Disclosure